Pharmacogenomic Study of Neoadjuvant Eribulin for HER2 Non-overexpressing Breast Cancer (NeoEribulin)

This study is currently recruiting participants.
Verified February 2013 by SOLTI Breast Cancer Research Group
Sponsor:
Collaborator:
Eisai Inc.
Information provided by (Responsible Party):
SOLTI Breast Cancer Research Group
ClinicalTrials.gov Identifier:
NCT01669252
First received: August 9, 2012
Last updated: February 11, 2013
Last verified: February 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: August 2017
  Estimated Primary Completion Date: August 2014 (Final data collection date for primary outcome measure)